Merck SG&A Expenses 2010-2024 | MKKGY
Merck annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Merck sg&a expenses for the quarter ending June 30, 2024 were $1.596B, a 1.37% decline year-over-year.
- Merck sg&a expenses for the twelve months ending June 30, 2024 were $6.331B, a 0.62% decline year-over-year.
- Merck annual sg&a expenses for 2023 were $6.388B, a 0.71% increase from 2022.
- Merck annual sg&a expenses for 2022 were $6.343B, a 3.32% decline from 2021.
- Merck annual sg&a expenses for 2021 were $6.56B, a 6.45% increase from 2020.
Merck Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$6,388 |
| 2022 |
$6,343 |
| 2021 |
$6,560 |
| 2020 |
$6,163 |
| 2019 |
$6,418 |
| 2018 |
$6,350 |
| 2017 |
$6,366 |
| 2016 |
$5,954 |
| 2015 |
$5,293 |
| 2014 |
$5,993 |
| 2013 |
$4,791 |
| 2012 |
$5,260 |
| 2011 |
$4,847 |
| 2010 |
$ |
| 2009 |
$ |
Merck Quarterly SG&A Expenses
(Millions of US $) |
| 2024-06-30 |
$1,596 |
| 2024-03-31 |
$1,541 |
| 2023-12-31 |
$1,654 |
| 2023-09-30 |
$1,541 |
| 2023-06-30 |
$1,618 |
| 2023-03-31 |
$1,575 |
| 2022-12-31 |
$1,616 |
| 2022-09-30 |
$1,562 |
| 2022-06-30 |
$1,623 |
| 2022-03-31 |
$1,542 |
| 2021-12-31 |
$1,778 |
| 2021-09-30 |
$1,623 |
| 2021-06-30 |
$1,617 |
| 2021-03-31 |
$1,543 |
| 2020-12-31 |
$1,721 |
| 2020-09-30 |
$1,487 |
| 2020-06-30 |
$1,468 |
| 2020-03-31 |
$1,487 |
| 2019-12-31 |
$1,734 |
| 2019-09-30 |
$1,520 |
| 2019-06-30 |
$1,603 |
| 2019-03-31 |
$1,561 |
| 2018-12-31 |
$1,578 |
| 2018-09-30 |
$1,531 |
| 2018-06-30 |
$1,602 |
| 2018-03-31 |
$1,640 |
| 2017-12-31 |
$1,649 |
| 2017-09-30 |
$1,593 |
| 2017-06-30 |
$1,621 |
| 2017-03-31 |
$1,503 |
| 2016-12-31 |
$1,575 |
| 2016-09-30 |
$1,454 |
| 2016-06-30 |
$1,494 |
| 2016-03-31 |
$1,430 |
| 2015-12-31 |
$1,778 |
| 2015-09-30 |
$1,336 |
| 2015-06-30 |
$1,380 |
| 2015-03-31 |
$1,294 |
| 2014-12-31 |
$2,005 |
| 2014-09-30 |
$1,401 |
| 2014-06-30 |
$1,375 |
| 2014-03-31 |
$1,213 |
| 2013-12-31 |
$1,393 |
| 2013-09-30 |
$1,093 |
| 2013-06-30 |
$1,136 |
| 2013-03-31 |
$1,169 |
| 2012-12-31 |
|
| 2012-09-30 |
$1,232 |
| 2012-06-30 |
$1,604 |
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
$1,442 |
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
$1,022 |
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$21.306B |
$22.719B |
|
Merck is a global pharmaceutical and chemical company. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
|
